CN114177239A - 一种膏药及其制备方法 - Google Patents
一种膏药及其制备方法 Download PDFInfo
- Publication number
- CN114177239A CN114177239A CN202210056504.XA CN202210056504A CN114177239A CN 114177239 A CN114177239 A CN 114177239A CN 202210056504 A CN202210056504 A CN 202210056504A CN 114177239 A CN114177239 A CN 114177239A
- Authority
- CN
- China
- Prior art keywords
- parts
- plaster
- decocting
- blood
- ointment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011505 plaster Substances 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 241000218176 Corydalis Species 0.000 claims abstract description 12
- 239000004863 Frankincense Substances 0.000 claims abstract description 12
- 241000195954 Lycopodium clavatum Species 0.000 claims abstract description 12
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 11
- 235000006226 Areca catechu Nutrition 0.000 claims abstract description 11
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 11
- 241001071917 Lithospermum Species 0.000 claims abstract description 11
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 11
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 10
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 10
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 10
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 10
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 10
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 10
- 241000131329 Carabidae Species 0.000 claims abstract description 9
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 9
- 239000009136 dragon's blood Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- 241000736246 Pyrola Species 0.000 claims abstract description 8
- 241000427159 Achyranthes Species 0.000 claims abstract description 7
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 7
- 240000005779 Jasminum multiflorum Species 0.000 claims abstract description 7
- 244000047734 Paederia foetida Species 0.000 claims abstract description 7
- 235000019116 Paederia foetida Nutrition 0.000 claims abstract description 7
- 241000725145 Homalomena Species 0.000 claims abstract description 6
- 240000004824 Trimezia steyermarkii Species 0.000 claims abstract description 6
- 244000235603 Acacia catechu Species 0.000 claims abstract description 3
- 230000008569 process Effects 0.000 claims abstract description 3
- 240000002045 Guettarda speciosa Species 0.000 claims abstract 2
- 239000002674 ointment Substances 0.000 claims description 36
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 30
- 239000008158 vegetable oil Substances 0.000 claims description 30
- 239000002994 raw material Substances 0.000 claims description 28
- 239000000706 filtrate Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 claims description 13
- 238000002791 soaking Methods 0.000 claims description 13
- 239000004745 nonwoven fabric Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 235000013871 bee wax Nutrition 0.000 claims description 10
- 239000012166 beeswax Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 239000003549 soybean oil Substances 0.000 claims description 6
- 235000012424 soybean oil Nutrition 0.000 claims description 6
- 241000501743 Gentiana macrophylla Species 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 244000195896 dadap Species 0.000 claims description 4
- 235000021388 linseed oil Nutrition 0.000 claims description 4
- 239000000944 linseed oil Substances 0.000 claims description 4
- 239000008159 sesame oil Substances 0.000 claims description 4
- 235000011803 sesame oil Nutrition 0.000 claims description 4
- 238000002137 ultrasound extraction Methods 0.000 claims description 4
- 235000019483 Peanut oil Nutrition 0.000 claims description 3
- 239000000312 peanut oil Substances 0.000 claims description 3
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 82
- 210000004369 blood Anatomy 0.000 abstract description 42
- 239000008280 blood Substances 0.000 abstract description 42
- 230000001737 promoting effect Effects 0.000 abstract description 38
- 208000002193 Pain Diseases 0.000 abstract description 35
- 230000036407 pain Effects 0.000 abstract description 34
- 206010061218 Inflammation Diseases 0.000 abstract description 17
- 230000004054 inflammatory process Effects 0.000 abstract description 17
- 230000003213 activating effect Effects 0.000 abstract description 16
- 230000017531 blood circulation Effects 0.000 abstract description 15
- 230000003467 diminishing effect Effects 0.000 abstract description 14
- 208000014674 injury Diseases 0.000 abstract description 12
- 230000006870 function Effects 0.000 abstract description 10
- 210000002435 tendon Anatomy 0.000 abstract description 10
- 230000008736 traumatic injury Effects 0.000 abstract description 9
- 208000010392 Bone Fractures Diseases 0.000 abstract description 6
- 230000002040 relaxant effect Effects 0.000 abstract description 6
- 206010050296 Intervertebral disc protrusion Diseases 0.000 abstract description 5
- 206010050031 Muscle strain Diseases 0.000 abstract description 5
- 230000004044 response Effects 0.000 abstract description 4
- 201000004595 synovitis Diseases 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 29
- 239000003814 drug Substances 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 17
- 230000008961 swelling Effects 0.000 description 17
- 210000002216 heart Anatomy 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 14
- 230000001603 reducing effect Effects 0.000 description 14
- 210000000988 bone and bone Anatomy 0.000 description 13
- 241001676573 Minium Species 0.000 description 12
- 230000000202 analgesic effect Effects 0.000 description 11
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 9
- 244000080767 Areca catechu Species 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000000740 bleeding effect Effects 0.000 description 8
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 206010000269 abscess Diseases 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 235000019640 taste Nutrition 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 206010061363 Skeletal injury Diseases 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 239000012466 permeate Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 244000061520 Angelica archangelica Species 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010017076 Fracture Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 240000000031 Achyranthes bidentata Species 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 241001489978 Eupolyphaga Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 208000026137 Soft tissue injury Diseases 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000008338 local blood flow Effects 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 210000001640 nerve ending Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000002633 protecting effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- -1 triterpene alcohol compounds Chemical class 0.000 description 3
- AEQDJSLRWYMAQI-QGZVFWFLSA-N (13ar)-2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5h-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-QGZVFWFLSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000213006 Angelica dahurica Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000717739 Boswellia sacra Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000123866 Homalomena occulta Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- BCZFSDNVXODRAJ-JTTNIQEDSA-N lycopodine Chemical compound C1CCN2CCC[C@@H]3[C@H]4C[C@@H](C)C[C@]32[C@H]1C(=O)C4 BCZFSDNVXODRAJ-JTTNIQEDSA-N 0.000 description 2
- BCZFSDNVXODRAJ-ZHMBSYLPSA-N lycopodine Natural products C1CCN2CCC[C@@H]3[C@H]4C[C@H](C)C[C@]32[C@H]1C(=O)C4 BCZFSDNVXODRAJ-ZHMBSYLPSA-N 0.000 description 2
- 210000001365 lymphatic vessel Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- YLYBTZIQSIBWLI-UHFFFAOYSA-N octyl acetate Chemical compound CCCCCCCCOC(C)=O YLYBTZIQSIBWLI-UHFFFAOYSA-N 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000004223 radioprotective effect Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- CUXYLFPMQMFGPL-UHFFFAOYSA-N (9Z,11E,13E)-9,11,13-Octadecatrienoic acid Natural products CCCCC=CC=CC=CCCCCCCCC(O)=O CUXYLFPMQMFGPL-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- HMMGKOVEOFBCAU-UHFFFAOYSA-N AKBA Natural products C1CC(OC(C)=O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CC(=O)C3C21C HMMGKOVEOFBCAU-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 1
- 239000004229 Alkannin Substances 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010064210 Bone fissure Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 241000208421 Ericaceae Species 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241001604597 Pyrestini Species 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WNFXUXZJJKTDOZ-HNNXBMFYSA-N [(1s)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] acetate Chemical compound C1=CC(O)=C2C(=O)C([C@@H](OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-HNNXBMFYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 1
- 235000019232 alkannin Nutrition 0.000 description 1
- CUXYLFPMQMFGPL-SUTYWZMXSA-N all-trans-octadeca-9,11,13-trienoic acid Chemical compound CCCC\C=C\C=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-SUTYWZMXSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- VRSRXLJTYQVOHC-YEJXKQKISA-N corydaline Chemical compound C=1([C@H]2[C@H]3C)C=C(OC)C(OC)=CC=1CCN2CC1=C3C=CC(OC)=C1OC VRSRXLJTYQVOHC-YEJXKQKISA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003933 gonadotropin antagonist Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- XDROKJSWHURZGO-UHFFFAOYSA-N isopsoralen Natural products C1=C2OC=CC2=C2OC(=O)C=CC2=C1 XDROKJSWHURZGO-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036445 liquid secretion Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- MLMVLVJMKDPYBM-UHFFFAOYSA-N pseudoisopsoralene Natural products C1=C2C=COC2=C2OC(=O)C=CC2=C1 MLMVLVJMKDPYBM-UHFFFAOYSA-N 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- WNFXUXZJJKTDOZ-UHFFFAOYSA-N shikonin acetate Natural products C1=CC(O)=C2C(=O)C(C(OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-UHFFFAOYSA-N 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009284 tracheal contraction Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/241—Lead; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Insects & Arthropods (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Husbandry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种膏药及其制备方法,涉及膏药制剂技术领域。该膏药,按重量份数计,包括:1‑10份鹿衔草,5‑15份络石藤,2‑9份伸筋草,5‑15份红花,8‑20份首乌藤,3‑10份川芎,2‑8份牛膝,7‑15份当归,2‑7份紫草,5‑12份乳香,4‑14份没药,2‑9份白芷,1‑8份血竭,1‑9份儿茶,3‑12份鸡屎藤,2‑7份千年健,1‑8份元胡和4‑13份土虫。本发明的膏药有活血化瘀、舒筋活络、消炎镇痛的作用,用于跌打损伤、骨裂骨折、腰间盘突出、腰肌劳损和滑膜炎,且疗效好,起效快。本发明的膏药的制备方法,其工艺简单,易于操作,便于生产。
Description
技术领域
本发明涉及膏药制剂技术领域,具体而言,涉及一种膏药及其制备方法。
背景技术
骨折、骨裂、颈、肩、腰、腿痛等筋骨伤痛临床上的治疗方法是采用手术和保守治疗。保守治疗的用药途径一般是通过静脉输液给药、肌肉注射和口服用药,但这种治疗方法对人体损伤重、愈合慢、费用高。静脉输液给药、肌肉注射和口服用药都使药物渗透全身,对人体局部器官和组织的病灶药力不集中,疗效差,且有过敏、胃肠道不适等副作用。
中医药采用膏药治疗外科病的历史非常悠久,治疗范围包括各种骨伤、创伤、软组织损伤、痈、疖、疔、疮等,尤其对于各种部位骨折、创伤和软组织损伤疗效独特,但是疗程长、见效慢,导致长时间使用药膏,有时会导致患者出现皮肤过敏甚至溃烂现象,给患者带来新的痛苦。因此提供一种能够显著治疗各种骨伤、创伤或软组织损伤的膏药是十分必要的。
发明内容
本发明的目的在于提供一种膏药,具有活血化瘀、舒筋活络、消炎镇痛的作用,用于跌打损伤、骨裂骨折、腰间盘突出、腰肌劳损和滑膜炎,且疗效好,起效快。
本发明的另一目的在于提供一种膏药的制备方法,其工艺简单,易于操作,便于生产。
本发明解决其技术问题是采用以下技术方案来实现的。
本发明提出一种膏药,按重量份数计,包括以下原料:1-10份鹿衔草,5-15份络石藤,2-9份伸筋草,5-15份红花,8-20份首乌藤,3-10份川芎,2-8份牛膝,7-15份当归,2-7份紫草,5-12份乳香,4-14份没药,2-9份白芷,1-8份血竭,1-9份儿茶,3-12份鸡屎藤,2-7份千年健,1-8份元胡和4-13份土虫。
本发明提出一种膏药的制备方法,包括以下步骤:
先将原料用温水浸泡30-50min,再加热煎煮1-2h,过滤得滤液,将滤液继续煎煮50-80min,加入植物油,在40-50℃熬制2-4h,得到浓汁,边搅拌浓汁边加入章丹,然后在5-10℃放置7-10d,再在60-70℃熬制10-20min,得到药膏。
本发明实施例至少具有以下有益效果:
本发明中,以鹿衔草、红花和川芎为主,辅以其余药材,使得膏药可以开结行滞直达病所,可透入皮肤产生消炎、止血、活血化瘀、通经走络、开窍透骨、祛风散寒等功效,刺激神经末梢,通过反射,扩张血管,促进局部血液循环,改善周围组织营养,达到消肿、消炎和镇痛的目的。同时药物在患处通过皮肤渗透达皮下组织,在局部产生药物浓度的相对优势,从而发挥较强的药理作用。其次,伸筋草、牛膝、紫草和元胡具有刺激作用,而强刺激通过神经反射,可以调节肌体功能促进抗体形成,提高人体免疫力,药物穿通皮肤及黏膜后,经过血管或淋巴管进入体循环,还可经过经络、脏腑进入体循环,起到调气血、通经络、散寒湿、消肿痛的作用,且各药物的通经络作用相互促进,可以进一步加快药物在机体中的运输和代谢,增强药效,进而产生全身性药物作用。此外,伸筋草、乳香、没药、血竭、儿茶和土虫搭配,续筋接骨作用与生肌作用配合,可以进一步加快骨伤恢复,促进愈合。采用纯中药材,通过合理配比,让中药的药性进行调理,相互渗透,能改善血液循环、抑制患处增生,起到消肿止痛、活血化瘀、温经通络的作用,进而有效治疗腰间盘突出、腰肌劳损、跌打损伤等,且疗效好,起效快,能够减少发病且愈后不复发。
本发明中,通过浸泡、煎煮、熬制即可得到药膏,其制作工艺简单,易于操作,便于生产。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将对本发明实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
需要说明的是,在不冲突的情况下,本申请中的实施例及实施例中的特征可以相互组合。下面将参考具体实施例来详细说明本发明。
一种膏药,按重量份数计,包括以下原料:1-10份鹿衔草,5-15份络石藤,2-9份伸筋草,5-15份红花,8-20份首乌藤,3-10份川芎,2-8份牛膝,7-15份当归,2-7份紫草,5-12份乳香,4-14份没药,2-9份白芷,1-8份血竭,1-9份儿茶,3-12份鸡屎藤,2-7份千年健,1-8份元胡和4-13份土虫。
鹿衔草,性温,味甘、苦,归肝经、肾经,具有祛风湿、强筋骨、止血、止咳之效,用于风湿痹痛、腰膝无力、失眠、月经过多、吐血鼻衄、久咳劳嗽、崩漏带下、外伤出血等。其有抗炎、扩张心脑血管、增强心脏收缩力、降压、抑菌、调节免疫作用。鹿衔草中的鹿蹄草素对金黄色葡萄球菌、伤寒杆菌、痢疾杆菌、溶血性链球菌、肺炎球菌、脑膜炎球菌及绿脓杆菌等均有抑制作用。
络石藤,味苦,性微寒,归心经、肝经、肾经,有祛风通络、凉血消肿之效,有抑菌、抗痛风作用,还有影响中枢神经,使呼吸加快,大剂量引起呼吸衰竭,对心脏作用较弱,对离体肠及子宫有抑制作用。
伸筋草,味微苦、辛,性温,归肝、脾、肾经,具有清热,止血,生肌,利湿,止痛,通络,祛风散寒,除湿消肿,舒筋活络,止咳,解毒等功效。伸筋草孢子主要含脂肪油、甾醇、挥发油、糖类,全草主要含石松碱、棒石松宁碱、棒石松毒碱和烟碱等,还含多种三萜醇化合物等。石松碱有明显的解热镇痛、抗炎作用。伸筋草可以通过调节细胞因子的水平抑制RF,从而起到治疗或减轻关节疼痛症状;还可以通过免疫调节机制,减少炎性因子表达,起到抗炎作用。
红花,性温,味辛,归心经、肝经,有活血通经、散瘀止痛之效,有轻度兴奋心脏、降低冠脉阻力、增加冠脉流量和心肌营养性血流量的作用;抗心肌缺血、心肌梗死、心律失常;改善外周微循环障碍;抗凝血;降血脂;提高耐缺氧能力;兴奋子宫;缓解肠道痉挛;具有免疫活性和抗炎作用;能减轻脑组织中单胺类神经介质的代谢紊乱;可致突变;对血管有明显的直接收缩作用;红花黄色素能明显延长小鼠左肺缺氧环境的生存时间;对ADP引起的血小板聚集有明显的抑制作用;有镇痛作用。
首乌藤,性平,味甘,归心经、肝经,有养血安神、祛风通络之效。其主含蒽醌类化合物,有大黄素、大黄酚、大黄素甲醚、β-谷甾醇,有镇静催眠作用,与戊巴比妥钠合用有明显的协同作用;首乌藤醇提取物能抑制实验性大鼠高脂血症;对实验性动脉粥样硬化有一定防治作用;并能促进免疫功能。
川芎,性温,味辛,归肝经、胆经、心包经,有活血行气、祛风止痛之效。其对心脏有抑制作用;可扩血管,降血压;增加冠脉流量;对心肌及再灌注损伤有保护作用;改善微循环;改善脑循环及脑缺血。改善血液系统、利尿、增强免疫系统;可抑制白三烯、组胺、前列腺素E2引起的气管收缩;能预防和保护肾上腺素所致大鼠实验性肺水肿;有抗肿瘤及抗放射等作用。
牛膝,性平,味苦、酸,归肝经、肾经,具有补肝肾、强筋骨、逐瘀通经、引血下行之效。牛膝提取物有抗炎镇痛作用和降血糖、降血脂等作用。对免疫功能正常或低下动物均有免疫增强作用,对细胞免疫和体液免疫均能增强。此外,还有延缓衰老和抗肿瘤的作用,对心脏有一定抑制作用,可扩张血管、降压,具有抗溃疡、抗炎镇痛、利胆、兴奋子宫、抗生育、抗凝血、抗瘀、降血糖、降脂、蛋白同化、增强免疫力、延缓衰老、利尿等作用。
当归,性温,味甘、辛,归肝经、心经、脾经,具有补血活血、调经止痛、润肠通便之效。当归有降低血小板聚集及抗血栓的功效与作用;促进造血系统功能;降血脂及抗动脉硬化;抗氧化和清除自由基;增强免疫系统功能;抑制I、Ⅱ、Ⅲ、Ⅳ型变态反应;对子宫具有兴奋及抑制的双向性作用;抑制前列腺增生;抗促性腺激素;抗辐射损伤;抗肿瘤;抗炎镇痛、抗损伤;保肝,利胆,促进消化,抑制胃肠的推动运动;具有抑制神经系统、松弛气管平滑肌、利尿、抑菌等作用。
紫草,性寒,味甘、咸,归心经、肝经,具有凉血、活血、解毒透疹之效,还具有抗炎、解热、镇静、镇痛、抗病原微生物、抗肿瘤、抗生育、兴奋平滑等作用。紫草中的紫草素及乙酰紫草素是抗炎症的主要成分,对血管通透性亢进和浮肿等炎症有明显抑制作用,可增加肉芽生长,促进伤口愈合。紫草对金黄色葡萄球菌、大肠杆菌、枯草杆菌等具有抑制作用,可以降低伤口感染风险,更便于伤口恢复。
乳香,性温,味辛、苦,归心经、脾经、肝经,具有调气活血、定痛、消肿、生肌之效,其含有的挥发油为镇痛的主要成分,主要为具镇痛作用的乙酸正辛酯。乳香能直接作用于神经末梢,抑制毛细血管通透性,改善局部血液循环,促进病灶处渗出液的吸收,达到消肿止痛的目的。乳香提取物中的3α-乙酰基-11-酮基-β-乳香酸(ABAK),能抑制5-脂氧化酶的活性,从而起到抗炎作用。
没药,性平,味辛、苦,归心经、肝经、脾经,具有散瘀定痛,消肿生肌之效。没药中含有挥发油、树脂、树胶和苦味素,具有抗炎、镇痛、抗肿瘤、降血脂、粘膜保护等作用。其能抑制角叉菜胶与棉球肉芽肿所致的炎症,起到消炎退热之效。此外,没药还有活血止血、抗菌、通经活络作用。
白芷含挥发油,又含比克一白芷素、新比克一、白芷醚及白芷毒素等,有解表、祛风、止痛、镇痛、抗菌作用,还有抗炎、解热、解痉作用。其通过祛风解表、散寒止痛、除湿通窍、消肿排脓之效,可以改善人体微循环,促进皮肤新陈代谢,消除色素在组织中过度堆积,降低瘢痕产生的机率,促进皮肤愈合。
血竭,性平,味甘、咸,归心经、肝经,有祛瘀定痛、止血生肌之效,用治跌打损伤、内伤瘀痛、外伤出血不止。其有抗炎、抑菌、抗血栓作用,对环核苷酸有影响,影响纤维蛋白溶解活性等。
儿茶,性微寒,味苦、涩,归肺经、心经,具有收湿、生肌、敛疮、止血之效,还有保肝利胆、调节免疫系统的功能、抗病原微生物、降低血糖、抑制胃肠道运动、抗腹泻作用;抗血小板聚集和抗血栓形成,降低血清胆固醇含量,降低组织耗氧量,尤其是心肌耗氧量,降低血压,调节心血管系统功能;儿茶有一定镇痛、抗放射、升高白细胞和抗肿瘤作用,并因能抑制瘤细胞与纤微蛋白粘连而阻止瘤细胞扩散。
鸡屎藤具有祛风活血,止痛解毒,消食导滞,除湿消肿的功效。与紫苏配合,可增强解毒镇痛之效,散郁气,对跌打损伤有较好的治疗效果。
千年健有祛风湿、健筋骨、抗组胺、抗凝血、抗菌、抗病毒、抗炎镇痛、消肿的功效,对于关节疼痛、筋骨无力有较好疗效。与牛膝配合,可增强壮筋骨的作用,可有效降低筋骨疼痛,加快骨伤恢复。此外,其还能去风通络,逐痹止痛。
元胡有活血散瘀、利气止痛的功效。元胡既入血分,又入气分,既能行血中之气,又能行气中之血,气血畅通,通则不痛,从而具有较强的镇痛作用。与当归、川芎配合,可加快四肢气血通畅,从而有效缓解四肢血滞疼痛。元胡中含有的延胡索甲素、乙素、丑素、癸素均具有镇痛作用,延胡索乙素镇痛作用最强。
土虫具有破血逐瘀、续筋接骨之效,主治血瘀经闭,症瘕积块,跌打瘀肿,筋骨骨折。土虫提取液可使血细胞比容、高切粘度、全血低切黏度等明显降低,具有抗凝血和抗血栓作用,对内皮细胞有保护作用。土虫能提高红细胞的CR1活性,提高红细胞免疫黏附能力,使血清中锌、钙含量增高;还具有抗突变能力,具有促进骨折愈合作用。
以鹿衔草、红花和川芎为主,辅以其余药材,使得膏药可以开结行滞直达病所,可透入皮肤产生消炎、止血、活血化瘀、通经走络、开窍透骨、祛风散寒等功效,刺激神经末梢,通过反射,扩张血管,促进局部血液循环,改善周围组织营养,达到消肿、消炎和镇痛的目的。同时药物在患处通过皮肤渗透达皮下组织,在局部产生药物浓度的相对优势,从而发挥较强的药理作用。其次,伸筋草、牛膝、紫草和元胡具有刺激作用,而强刺激通过神经反射,可以调节肌体功能促进抗体形成,提高人体免疫力,药物穿通皮肤及黏膜后,经过血管或淋巴管进入体循环,还可经过经络、脏腑进入体循环,起到调气血、通经络、散寒湿、消肿痛的作用,进而产生全身性药物作用。此外,伸筋草、乳香、没药、血竭、儿茶和土虫搭配,续筋接骨作用与生肌作用配合,可以进一步加快骨伤恢复。
本实施例中,采用纯中药材,通过合理配比,让中药的药性进行调理,相互渗透,能改善血液循环、抑制患处增生,起到消肿止痛、活血化瘀、温经通络的作用,进而有效治疗腰间盘突出、腰肌劳损、跌打损伤等,且疗效好,起效快,能够减少发病且愈后不复发。
本实施例中,按重量份数计,膏药还包括800-1500份植物油和400-600份章丹。
植物油,是由高级脂肪酸和甘油反应而成的化合物,主要成分是直链高级脂肪酸和甘油生成的酯,脂肪酸除软脂酸、硬脂酸和油酸外,还含有多种不饱和酸,如芥酸、桐油酸、蓖麻油酸等。植物油主要含有维生素E、维生素K、钙、铁、磷、钾等矿物质、脂肪酸等。植物油中的脂肪酸能使皮肤滋润有光泽。植物油可以使制得的膏药色泽光亮、粘性好、质量好。章丹,辛,微寒,有毒,归心、入脾、肝经,外用拔毒生肌、杀虫止痒,能直接杀灭细菌寄生虫,有制止粘液分泌的作用。
以植物油为载体,将各药材的有效成分进行融合,利用油性物质的挥发性,使得药膏更易于渗透进皮肤,让皮肤更好更快地吸收药膏的有效成分,更利于对病灶部位进行治疗,从而提高疗效,加快治疗速度。搭配章丹,可以进一步提高药膏的拔毒生肌之效,且还可以防止患处液体分泌,进而保持患处干爽,加快患处恢复。植物油为豆油、花生油、亚麻籽油、芝麻油和菜籽油中的一种或多种。上述植物油更便于皮肤吸收,且营养成分更充分,更有利于受损组织恢复,进而增强消炎、消肿之效。
一种膏药的制备方法,包括以下步骤:
先将原料用温水浸泡30-50min,再加热煎煮1-2h,过滤得滤液,将滤液继续煎煮50-80min,加入植物油,在40-50℃熬制2-4h,得到浓汁,边搅拌浓汁边加入章丹,然后在5-10℃放置7-10d,再在60-70℃熬制10-20min,得到药膏。
先将原料用温水浸泡30-50min,再加热煎煮1-2h,过滤得滤液。温水浸泡后原料中的有效成分更容易萃取出来,使得有效成分含量提高,进而增强对跌打损伤或滑膜炎的治疗效果。将滤液继续煎煮50-80min,加入植物油,在40-50℃熬制2-4h,得到浓汁。这样可以让植物油和有效成分混合效果更好,使得植物油更好地携带药用成分渗进皮肤,让膏药对患处的治疗效果更好。边搅拌浓汁边加入章丹,然后在5-10℃放置7-10d,再在60-70℃熬制10-20min,得到药膏。这样可以让章丹将药用成分包裹,让章丹先对患处进行消毒杀菌,让皮肤更便于吸收药用成分,使得膏药的使用效果更好。且通过放置、再熬煮,可以进一步使得膏药中的成分混合效果更好,进而增强药物疗效。
还包括向过滤后的滤渣中加入乙醇,超声提取1-3次,每次提取1-2h,收集提取液,将提取液在60-70℃浓缩30-50min,得到浓缩液,将浓缩液和滤液混合。这样可以进一步将滤渣中的药用成分提取出来,而且通过超声提取可以确保将滤渣中的药用成分尽可能多的提取出来,使得其含量增多,效用增强。
原料用温水浸泡之前,还包括将原料研磨成细粉,过120-150目筛。这样可以快速将原料中的有效成分提取出来,而且提取效果更好,有效成分提取更充分。
章丹的加入速率为5-10g/min。在该速率下,可以避免章丹分散不均匀,使得药膏的均一性较差,从而使得膏药效果不理想。
在加热熬煮1-2h之前,还包括加入按重量份数计的秦艽1-5份和海桐皮5-10份。秦艽,性平,味苦、辛,归胃经、肝经、胆经,有祛风湿、退虚热、舒筋止疼之效。海桐皮有镇痛消炎、祛风行气、祛湿活血之效,根皮治胃炎、肾炎及风湿疼痛,亦可外敷刀伤,有祛风湿、通经络、杀虫作用,可以治风湿痹痛、痢疾、牙痛、疥癣。这样可以进一步增强膏药的祛风湿效果,进而增强止痛消炎之效。
还包括将药膏制成膏药贴,膏药贴包括无纺布和PE膜,将药膏涂抹在无纺布上,用量为5-10g/cm2,然后将PE膜与无纺布粘接,且药膏位于两者之间。在上述用量下,皮肤对药膏的吸收效果最好,对患处的治疗效果最佳,可以避免药膏浪费。
在将药膏涂抹在无纺布上之前,还包括向药膏中加入蜂蜡混合,且蜂蜡与药膏的质量比为(0.3-0.8):1。通过蜂蜡将药膏包裹,使得蜂蜡在药膏外面形成一层保护膜,这样更便于储存,且在使用时,通过患处发热使得蜂蜡溶解,从而让药膏渗出被皮肤吸收,这样可以加快皮肤吸收药用成分的速率,使得膏药起效快。
以下结合实施例对本发明的特征和性能作进一步的详细描述。
实施例1
一种膏药,包括以下原料:1g鹿衔草,5g络石藤,2g伸筋草,5g红花,8g首乌藤,3g川芎,2g牛膝,7g当归,2g紫草,5g乳香,4g没药,2g白芷,1g血竭,1g儿茶,3g鸡屎藤,2g千年健,1g元胡,4g土虫,800g植物油和400g章丹。
一种膏药的制备方法,包括以下步骤:
先将原料用温水浸泡30min,再加热煎煮1h,过滤得滤液,将滤液继续煎煮50min,加入植物油,在40℃熬制2h,得到浓汁,边搅拌浓汁边加入章丹,然后在5℃放置7d,再在60℃熬制10min,得到药膏。
实施例2
一种膏药,包括以下原料:10g鹿衔草,15g络石藤,9g伸筋草,15g红花,20g首乌藤,10g川芎,8g牛膝,15g当归,7g紫草,12g乳香,14g没药,9g白芷,8g血竭,9g儿茶,12g鸡屎藤,7g千年健,8g元胡,13g土虫,1500g植物油和600g章丹。
一种膏药的制备方法,包括以下步骤:
先将原料用温水浸泡50min,再加热煎煮2h,过滤得滤液,将滤液继续煎煮80min,加入植物油,在50℃熬制4h,得到浓汁,边搅拌浓汁边加入章丹,然后在10℃放置10d,再在70℃熬制20min,得到药膏。
实施例3
一种膏药,包括以下原料:5g鹿衔草,10g络石藤,5g伸筋草,8g红花,10g首乌藤,5g川芎,5g牛膝,10g当归,5g紫草,8g乳香,8g没药,5g白芷,5g血竭,5g儿茶,8g鸡屎藤,5g千年健,5g元胡,8g土虫,1000g植物油和500g章丹。
一种膏药的制备方法,包括以下步骤:
先将原料用温水浸泡40min,再加热煎煮1.5h,过滤得滤液,将滤液继续煎煮60min,加入植物油,在45℃熬制3h,得到浓汁,边搅拌浓汁边加入章丹,然后在7℃放置8d,再在65℃熬制15min,得到药膏。
实施例4
本实施例中膏药原料及用量与实施例3相同,其中,植物油为豆油。
一种膏药的制备方法,包括以下步骤:
先将原料用温水浸泡40min,再加热煎煮1.5h,过滤得滤液和滤渣,向滤渣中加入乙醇,超声提取3次,每次提取2h,收集提取液,将提取液在70℃浓缩50min,得到浓缩液,将滤液和浓缩液合并后继续煎煮60min,加入植物油,在45℃熬制3h,得到浓汁,边搅拌浓汁边加入章丹,然后在7℃放置8d,再在65℃熬制15min,得到药膏。
实施例5
本实施例中膏药原料及用量与实施例3相同,其中,植物油为亚麻籽油和豆油的混合油。
一种膏药的制备方法,包括以下步骤:
先将原料研磨成细粉,过140目筛,将细粉用温水浸泡40min,再加热煎煮1.5h,过滤得滤液和滤渣,向滤渣中加入乙醇,超声提取2次,每次提取1.5h,收集提取液,将提取液在65℃浓缩40min,得到浓缩液,将滤液和浓缩液合并后继续煎煮60min,加入植物油,在45℃熬制3h,得到浓汁,边搅拌浓汁边加入章丹,然后在7℃放置8d,再在65℃熬制15min,得到药膏。
实施例6
本实施例中膏药原料及用量与实施例3相同,其中,植物油为亚麻籽油、芝麻油和豆油的混合油。
一种膏药的制备方法,包括以下步骤:
先将原料研磨成细粉,过130目筛,将细粉用温水浸泡40min,加入秦艽5g和海桐皮10g,再加热煎煮1.5h,过滤得滤液和滤渣,向滤渣中加入乙醇,超声提取3次,每次提取2h,收集提取液,将提取液在65℃浓缩40min,得到浓缩液,将滤液和浓缩液合并后继续煎煮60min,加入植物油,在45℃熬制3h,得到浓汁,边搅拌浓汁边加入章丹,章丹的加入速率为8g/min,然后在7℃放置8d,再在65℃熬制15min,得到药膏。
实施例7
本实施例中膏药原料及用量与实施例3相同,其中,植物油为花生油、芝麻油和豆油的混合油。
一种膏药的制备方法,包括以下步骤:
先将原料研磨成细粉,过130目筛,将细粉用温水浸泡40min,加入秦艽4g和海桐皮8g,再加热煎煮1.5h,过滤得滤液和滤渣,向滤渣中加入乙醇,超声提取3次,每次提取2h,收集提取液,将提取液在65℃浓缩40min,得到浓缩液,将滤液和浓缩液合并后继续煎煮60min,加入植物油,在45℃熬制3h,得到浓汁,边搅拌浓汁边加入章丹,章丹的加入速率为8g/min,然后在7℃放置8d,再在65℃熬制15min,得到药膏;向药膏中加入蜂蜡混合,且蜂蜡与药膏的质量比为0.3:1,再将其制成膏药贴,所述膏药贴包括无纺布和PE膜,将蜂蜡与药膏混合后的混合物涂抹在无纺布上,用量为5g/cm2,然后将PE膜与无纺布粘接,且混合物位于两者之间。
试验结果
1.选择20-22g昆明种小鼠80只,随机分为8组,每组10只,7个膏药组和1个对照组,将8组小鼠腹部脱毛,面积为1.5cm×1.5cm,且无皮肤破损,1-7组分别使用实施例1-7的膏药,将膏药贴于脱毛处,对照组在脱毛处贴纱布,用胶布固定,然后对每组小鼠注射0.7%冰醋酸溶液0.1/10g,观察并记录注射致痛剂后20min内各小鼠扭动次数,结果见表1。
表1止痛试验结果
根据表1可知,使用本发明实施例的膏药的小鼠平均扭动次数较对照组明显减少,因此表明本发明的膏药具有显著的止痛效果。且实施例7的膏药相比较其他实施例的膏药,其止痛效果最好。
2.选取昆明雄性小鼠20只,背部进行脱毛且无皮肤破损,脱毛24h后,用0.5%戊巴比妥钠(1mL/100g)麻醉后,在小鼠的脱毛区皮下注射金黄色葡萄球菌液(浓度为4.01×108cfu/mL)0.1mL/只,注射金黄色葡萄球菌24h后,将20只小鼠随机分为两组,对照组和膏药组,对照组不敷任何药物,膏药组给每只小鼠外敷实施例7制备的膏药,每天更换一次外敷膏药,连续外敷7天,结果如表2所示。
其中,需要说明的是,皮下注射金黄色葡萄球菌24h后,小鼠背部出现脓包。
表2脓肿消除率(%)
组别 | 1天 | 2天 | 3天 | 4天 | 5天 | 6天 | 7天 |
膏药组 | -30 | -54 | -34 | -15 | 35 | 80 | 98 |
对照组 | -32 | -58 | -52 | -48 | -35 | -38 | -30 |
注:脓肿消除率小于0为脓肿,大于0为消肿。
根据表2可知,前两天脓肿继续肿大,第3天和第4天膏药组的消肿速率比对照组显著提高,在5-7天,膏药组的脓肿消除速率快。由此可知,本发明制备的膏药可以加速脓肿消除,具有较好的拔脓消肿作用。
综上所述,本发明实施例的膏药,具有活血化瘀、舒筋活络、消炎镇痛的作用,用于跌打损伤、骨裂骨折、腰间盘突出、腰肌劳损和滑膜炎,且疗效好,起效快。
本发明实施例中膏药的制备方法,通过浸泡、煎煮、熬制即可得到药膏,其制作工艺简单,易于操作,便于生产。
以上所描述的实施例是本发明一部分实施例,而不是全部的实施例。本发明的实施例的详细描述并非旨在限制要求保护的本发明的范围,而是仅仅表示本发明的选定实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
Claims (10)
1.一种膏药,其特征在于,按重量份数计,包括以下原料:1-10份鹿衔草,5-15份络石藤,2-9份伸筋草,5-15份红花,8-20份首乌藤,3-10份川芎,2-8份牛膝,7-15份当归,2-7份紫草,5-12份乳香,4-14份没药,2-9份白芷,1-8份血竭,1-9份儿茶,3-12份鸡屎藤,2-7份千年健,1-8份元胡和4-13份土虫。
2.根据权利要求1所述的膏药,其特征在于,按重量份数计,还包括800-1500份植物油和400-600份章丹。
3.根据权利要求2所述的膏药,其特征在于,所述植物油为豆油、花生油、亚麻籽油、芝麻油和菜籽油中的一种或多种。
4.一种如权利要求1-3任一项所述的膏药的制备方法,其特征在于,包括以下步骤:
先将原料用温水浸泡30-50min,再加热煎煮1-2h,过滤得滤液,将所述滤液继续煎煮50-80min,加入植物油,在40-50℃熬制2-4h,得到浓汁,边搅拌所述浓汁边加入章丹,然后在5-10℃放置7-10d,再在60-70℃熬制10-20min,得到药膏。
5.根据权利要求4所述的制备方法,其特征在于,还包括向过滤后的滤渣中加入乙醇,超声提取1-3次,每次提取1-2h,收集提取液,将所述提取液在60-70℃浓缩30-50min,得到浓缩液,将所述浓缩液和所述滤液混合。
6.根据权利要求4所述的制备方法,其特征在于,原料用温水浸泡之前,还包括将所述原料研磨成细粉,过120-150目筛。
7.根据权利要求4所述的制备方法,其特征在于,所述章丹的加入速率为5-10g/min。
8.根据权利要求4所述的制备方法,其特征在于,在加热熬煮1-2h之前,还包括加入按重量份数计的秦艽1-5份和海桐皮5-10份。
9.根据权利要求4所述的制备方法,其特征在于,还包括将所述药膏制成膏药贴,所述膏药贴包括无纺布和PE膜,将所述药膏涂抹在无纺布上,用量为5-10g/cm2,然后将所述PE膜与所述无纺布粘接,且所述药膏位于两者之间。
10.根据权利要求9所述的制备方法,其特征在于,在将所述药膏涂抹在无纺布上之前,还包括向所述药膏中加入蜂蜡混合,且所述蜂蜡与所述药膏的质量比为(0.3-0.8):1。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210056504.XA CN114177239A (zh) | 2022-01-18 | 2022-01-18 | 一种膏药及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210056504.XA CN114177239A (zh) | 2022-01-18 | 2022-01-18 | 一种膏药及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114177239A true CN114177239A (zh) | 2022-03-15 |
Family
ID=80545726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210056504.XA Pending CN114177239A (zh) | 2022-01-18 | 2022-01-18 | 一种膏药及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114177239A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102028833A (zh) * | 2009-09-24 | 2011-04-27 | 张立臣 | 一种治疗肩颈腰腿疼的膏药及制备方法 |
CN103191271A (zh) * | 2012-01-05 | 2013-07-10 | 范文强 | 一种祛痛消炎膏的制备方法 |
CN104013929A (zh) * | 2012-06-01 | 2014-09-03 | 通化金马药业集团股份有限公司 | 一种治疗风湿性关节炎和类风湿性关节炎的风湿祛痛药物及制备方法 |
CN105983036A (zh) * | 2015-01-30 | 2016-10-05 | 洪帆 | 一种治疗颈肩腰腿痛的膏药 |
-
2022
- 2022-01-18 CN CN202210056504.XA patent/CN114177239A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102028833A (zh) * | 2009-09-24 | 2011-04-27 | 张立臣 | 一种治疗肩颈腰腿疼的膏药及制备方法 |
CN103191271A (zh) * | 2012-01-05 | 2013-07-10 | 范文强 | 一种祛痛消炎膏的制备方法 |
CN104013929A (zh) * | 2012-06-01 | 2014-09-03 | 通化金马药业集团股份有限公司 | 一种治疗风湿性关节炎和类风湿性关节炎的风湿祛痛药物及制备方法 |
CN105983036A (zh) * | 2015-01-30 | 2016-10-05 | 洪帆 | 一种治疗颈肩腰腿痛的膏药 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103169928B (zh) | 治疗痛经的外用中药组合物及其制备方法和应用 | |
CN1709336A (zh) | 红外鼻炎贴及制备方法 | |
CN103877247A (zh) | 用于治疗褥疮的药物及其制备方法 | |
CN114177239A (zh) | 一种膏药及其制备方法 | |
CN109432203B (zh) | 用于治疗非哺乳期乳腺炎的药物组合物及中药原料组合物 | |
CN113230336A (zh) | 一种治疗肩颈腰腿痛的中药膏贴 | |
CN106361932A (zh) | 一种用于跌打损伤的外擦中药酊剂 | |
CN106729939B (zh) | 一种治疗褥疮的敷料 | |
CN113082089A (zh) | 一种治疗皮肤过敏的中药膏剂及其制备方法 | |
CN112691157A (zh) | 一种风湿类关节炎药材组合物的配方及制备方法 | |
CN105031380A (zh) | 一种用于孕妇口腔局部麻醉的药物及其制备方法 | |
CN101518579B (zh) | 一种稳压疏通药及制备工艺 | |
CN109394869A (zh) | 蒲蓉爽乳霜及其制备方法 | |
CN110585379A (zh) | 一种皮炎治疗外敷药物 | |
CN114469845B (zh) | 一种利用大胡蜂蜂针液的外用制剂及其制备方法 | |
CN113230332B (zh) | 一种治疗糖尿病患者伤口溃烂不能愈合的药物、其制剂及制法 | |
CN109846861B (zh) | 一种蒙药外用贴膏及其制备方法 | |
CN107041913B (zh) | 一种用于静脉输液所致静脉炎的中药组合物、喷雾剂及应用 | |
CN105381366A (zh) | 一种治疗褥疮的中药组合物及其制备方法 | |
CN105535853A (zh) | 一种临床护理上用于治疗褥疮的中药组合物 | |
CN105125781A (zh) | 一种治疗iii期压疮的中药凝胶剂及其制备方法 | |
CN113786451A (zh) | 一种用于治疗妇科肿瘤的中药组合物及制备方法 | |
CN114588226A (zh) | 一种治疗骨折的中药组合物及其制备方法 | |
CN110613177A (zh) | 一种防治男性前列腺的中草药内裤及其制备方法 | |
CN113633698A (zh) | 一种中药微针透皮给药药贴及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220315 |
|
RJ01 | Rejection of invention patent application after publication |